Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Gemcitabine in Advanced Metastatic Pancreatic Cancer
NCT02863367Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
Rivoceranib
Beyond the preview
Go deeper on NCT02863367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863367.